This common prescription drug could reduce deaths by sepsis, study finds
Critically ill patients with sepsis who are given statins may be more likely to survive, new research suggests.
Researchers set out to explore whether the cholesterol-busting drugs may bring additional benefits for patients.
The new study examined information on sepsis patients who received statins during a stint in intensive care and compared it with patients in a similar situation who did not receive statins.
Some 14.3 per cent of 6,000 sepsis patients who were given statins died within 28 days.
This is compared with 23.4 per cent of 6,000 patients who did not receive statin therapy.
The research team from China said that this equates to a 39 per cent reduced risk of death within a month.
The research, based on data from thousands of patients at a hospital in Israel between 2008 and 2019, also found that 7.4 per cent of statin patients died while in the intensive care unit compared with 13.6 per cent of those who did not receive statins.
And during their overall hospital stay, some 11.5 per cent of sepsis patients who were given statins died, compared with 19.1 per cent of sepsis patients who did not take statins.
However, it appeared that those who were not prescribed statins had a slightly shorter hospital stay compared with those who did receive them – an average of eight days compared with almost 10 days.
'We found that statin users exhibited decreased 28-day all-cause mortality,' the authors wrote in the journal Frontiers in Immunology.
Sepsis is a life-threatening reaction to an infection that occurs when the immune system overreacts and starts to damage the body's tissues and organs.
In the UK, 245,000 people are affected by sepsis every year.
UK sepsis experts said that 'anything which might reduce the burden of a condition which claims one in five lives worldwide needs to be rigorously explored' as they called for larger trials to confirm the findings.
Statins are known as cholesterol-busting drugs because they can help lower the level of low-density lipoprotein (LDL) cholesterol in the blood.
But experts said that they also have other benefits, including reducing inflammation and antibacterial effects.
The research team called for larger trials to confirm their findings.
'Our large, matched cohort study found that treatment with statins was associated with a 39 per cent lower death rate for critically ill patients with sepsis, when measured over 28 days after hospital admission,' said Dr Caifeng Li, the study's corresponding author and an associate professor at Tianjin Medical University General Hospital in China.
'These results strongly suggest that statins may provide a protective effect and improve clinical outcomes for patients with sepsis.'
Commenting on the study, Dr Ron Daniels, founder and chief executive of the UK Sepsis Trust, said: 'It has been known for some time that the anti-inflammatory properties of statins confer a survival benefit on those who take them if they develop sepsis.
'Whilst previous studies have failed to show a similar survival benefit in treating people with sepsis with statins, this new study supports calls for a large, multi-country, randomised control trial.
'Anything which might reduce the burden of a condition which claims one in five lives worldwide needs to be rigorously explored.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Health Line
3 hours ago
- Health Line
What's the Life Expectancy for Parkinson's Disease?
Key takeaways At age 65, patients with Parkinson's disease have a life expectancy reduced by 6.7 years compared to those without the disease, while at age 85, the difference in life expectancy is 1.2 years. Severe clinical milestones that can impact survival include visual hallucinations, recurrent falls, dementia, and placement in a nursing home. Each milestone may double the risk of death during a 10-year period. Males with Parkinson's disease may experience a greater reduction in life expectancy than females, and those diagnosed before age 70 typically see a larger decrease in life expectancy compared to later diagnoses. If you or a loved one has received a diagnosis of Parkinson's, you may be wondering how the disease may progress over time. Parkinson's disease is a slow, progressive disease. This means that symptoms gradually worsen over time. While Parkinson's disease itself isn't fatal, related complications can reduce life expectancy. The individual outlook can vary based on the severity of Parkinson's disease, a person's overall health, and the type of Parkinson's disease they have. Research from 2020 suggests that at 65 years, the life expectancy of patients with Parkinson's was reduced by 6.7 years compared to that of people without Parkinson's disease. At 85, the difference in life expectancy was 1.2 years. Keep reading to learn more about the disease course and outlook with Parkinson's disease and the factors that may inform a doctor's prediction about a person's outlook. Factors that affect the outlook with Parkinson's disease Symptoms and complications can affect the outlook of a person with Parkinson's disease. Symptoms and severity Research from 2022 suggests that the presence of certain severe clinical milestones may predict a person's disease course with Parkinson's disease and increase the risk of death. Each milestone may double the risk of death during a 10-year period. These milestones include: visual hallucinations recurrent falls dementia placement in a nursing home Parkinson's and falls Falls are a common secondary symptom of Parkinson's disease. The risk of falling increases in stages 3 and is greater in stages 4 and 5. In these stages, you may not be able to stand or walk on your own. You'll also be prone to broken bones and concussions, and severe falls can be dangerous. Complications from a serious fall can reduce your life expectancy. Age Age is another factor in the diagnosis and outlook for Parkinson's disease. Most people will receive a diagnosis after 70. As you get older, you may be more prone to falls and more likely to develop certain diseases, even if you don't have Parkinson's disease. These risks can increase if you have Parkinson's. Research from 2020 suggests that people who receive a diagnosis before age 70 usually experience a greater reduction in life expectancy: In people at age 55: a 10.1-year reduction In people at age 65: a 6.7-year reduction In people at age 75: a 3.5-year reduction In people at age 85: a 1.2-year reduction Sex Research suggests that males with Parkinson's may have a greater reduction in life expectancy than females. Access to treatment Life expectancy has increased significantly due to advances in treatment. Medications and physical and occupational therapy are especially helpful in the earliest stages of Parkinson's. These treatments can improve your quality of life. Type of disease The type of parkinsonism can also impact a person's life expectancy, according to 2020 research. People with atypical parkinsonism, including Lewy body dementia, progressive supranuclear palsy, and multiple system atrophy, have increased mortality compared to people with typical Parkinson's disease and people without Parkinson's disease. Long-term outlook Early detection of Parkinson's disease is key to helping reduce complications that can negatively affect the outlook. If you suspect that you or a loved one may have Parkinson's disease, consult a doctor right away. Parkinson's symptoms and severity by stage Doctors classify Parkinson's disease into stages 1 to 5, with stage 5 being the most advanced. Advanced stages may increase the risk of health complications that can reduce life span. The symptoms of Parkinson's are gradual and are sometimes not noticeable in the early stages of the disease. They may include: tremors loss of balance slowing of movements spontaneous, uncontrollable movements Symptoms in later stages of Parkinson's may include: more frequent falls trouble dressing difficulty eating swallowing severe stiffness in your legs, which makes it impossible to stand or walk hallucinations or delusions cognitive changes (problems with planning, language, attention, or memory) dementia lightheadedness mood disorders loss of sense of smell or taste vision problems sleep disorders sexual problems As Parkinson's progresses to stages 3, 4, and 5, the risk of falling may increase, and motor balance may worsen. Pneumonia, particularly aspiration pneumonia, is the leading cause of death for people with Parkinson's, accounting for 70% of Parkinson's deaths. Aspiration pneumonia happens when you inhale food, stomach acid, or saliva into the lungs. As Parkinson's progresses, swallowing can become more difficult, causing food and liquid to enter the lungs. Treatment may help reduce symptoms. Frequently asked questions Why does it take so long for a diagnosis of Parkinson's disease? There is no definitive medical test that can be performed to diagnose Parkinson's disease. It's essentially a clinical diagnosis, meaning a doctor will make the diagnosis based on several clinical features seen. Symptoms of Parkinson's disease include tremor, slowness of movement, stiffness, and balance problems. However, the presentation and progression of these symptoms vary widely from person to person. The initial presentation is often subtle and may be similar to other conditions. Some people think their symptoms are due to normal aging, which may make them delay seeking medical attention. Another common finding in patients with Parkinson's disease is 'masked facies,' or an expressionless face, which often gets mistaken for depression. If there's concern that someone is developing Parkinson's disease, they should get a clinical exam from a neurologist to get a diagnosis. There is no definitive medical test that can be performed to diagnose Parkinson's disease. It's essentially a clinical diagnosis, meaning a doctor will make the diagnosis based on several clinical features seen. Symptoms of Parkinson's disease include tremor, slowness of movement, stiffness, and balance problems. However, the presentation and progression of these symptoms vary widely from person to person. The initial presentation is often subtle and may be similar to other conditions. Some people think their symptoms are due to normal aging, which may make them delay seeking medical attention. Another common finding in patients with Parkinson's disease is 'masked facies,' or an expressionless face, which often gets mistaken for depression. If there's concern that someone is developing Parkinson's disease, they should get a clinical exam from a neurologist to get a diagnosis. Is Parkinson's disease fatal? While Parkinson's disease is not fatal, it can cause complications that increase the risk of death. People with Parkinson's have a mortality rate 3 times that of people without Parkinson's. While Parkinson's disease is not fatal, it can cause complications that increase the risk of death. People with Parkinson's have a mortality rate 3 times that of people without Parkinson's. Can treatment help prevent Parkinson's disease complications? Parkinson's disease cannot be cured, but medications, supportive treatments, lifestyle changes, and even surgery can help manage your symptoms or delay more severe symptoms, especially if you start treatment early. This may reduce complications. Parkinson's disease cannot be cured, but medications, supportive treatments, lifestyle changes, and even surgery can help manage your symptoms or delay more severe symptoms, especially if you start treatment early. This may reduce complications.
Health Line
6 hours ago
- Health Line
Seeing a Psychiatrist for the First Time
At first, I was scared and overwhelmed by the thought of seeing a psychiatrist. The first psychiatric evaluation is, in my experience, the most intense and lengthy of your entrance into the world of seeing a psychiatrist. I've been going to the psychiatrist for over 5 years. Read on for more about my experience. Initial appointment My evaluation was in person with my doctor (in early 2020, pre-pandemic), and my partner also came along as a support person to provide his insight and answer questions as needed. My psychiatrist manages a mental health program at a hospital, and that's how I got connected with him for my first appointment. There are many ways to find a psychiatrist. Many psychiatrists do not take insurance, but some do. Your insurance may also reimburse you, if that's part of your plan. If you pay out of pocket, it can be expensive: I've been quoted anywhere from $400+ for the initial intake. Follow-up appointments are usually cheaper, but still cost at least $100 each. Some specialty mental health programs receive grants that may make the appointments more affordable. Ahead of the appointment, you might be asked to complete a questionnaire to help your psychiatrist evaluate your symptoms. The questionnaires are usually about anxiety, depression, and more. You'll also provide your family medical history, or what you know of it. Completing the questionnaires may feel overwhelming, so it's a good idea take breaks as you work your way through them, if you are able. It may also feel scary. For me, I worried that the psychiatrist was going to discover a new diagnosis that I had not already been given. That's probably a typical trauma response: 'What is wrong with me? Am I broken? Will I always feel like this?' were all thoughts that I had when initially accepting that I needed a psychiatrist for my mental healthcare. My first appointment was close to an hour long and involved a long conversation with my doctor. I felt mentally drained and exhausted afterward, so I rested for the afternoon. A few years later, I can say that having a psychiatrist whom I trust has made all the difference in my ability to care for myself and my mental health. Follow-up appointments Follow-ups tend to be shorter, at about 30 minutes or less, depending on how you're feeling. My psychiatrist and I chat about my mood and the potential side effects of the medications. We discuss how things are going in my life, including work, socialization, exercise, sleep, hobbies, energy levels, and more. It's not a therapy appointment, but more like a check-in about overall wellness. Then, we discuss any potential medication modifications, and my psychiatrist answers questions that I may have. Appointment frequency with your psychiatrist will vary based on your care. Follow-ups with my psychiatrist are more routine now; I go four times a year. It's important to meet with them periodically, as needed, depending on how you're doing. If I've made a medication change, whether switching to a different medication or upping or lowering a dose, I'll meet with them more frequently to check in. I now meet with my psychiatrist via video, using an app the hospital system utilizes for secure connection.
Medscape
6 hours ago
- Medscape
Nefecon Shows IgAN Benefits Regardless of Baseline eGFR
Nefecon, an oral targeted-release formulation of budesonide that targets drug release into the distal ileum, provided significant improvements in the loss of kidney function in patients with immunoglobulin A nephropathy (IgAN) at 9 months, regardless of baseline estimated glomerular filtration rate (eGFR) status, according to a new subanalysis of the phase 3 NeflgArd study. METHODOLOGY: Patients in the NeflgArd study with primary IgAN were randomly assigned to one of two groups of 182 patients each to receive either treatment with 16 mg Nefecon or placebo daily, along with supportive care with renin-angiotensin system inhibition. This was followed by a 15-month off-drug observational period allowing for continued supportive care. For the subanalysis, the patients were further stratified on the basis of eGFR deciles in relation to the overall study population, with levels above and below 38, 43, 47, 51, 55, 60, 66, 72, and 82 mL/min/1.73 m 2 . . The median eGFR overall was 55.49 mL/min/1.73 m2 and was balanced across the Nefecon and placebo groups. TAKEAWAY: The relative benefit of Nefecon in terms of eGFR was seen across most deciles and timepoints and showed a generally greater benefit in higher baseline eGFR groups (above 72 mL/min/1.73 m 2 ). ). Furthermore, the relative urine protein-creatinine ratio benefit was observed from month 9 with Nefecon vs placebo regardless of baseline eGFR, with a continued reduction to month 12, followed by a maintained treatment benefit to month 24. The eGFR benefits with Nefecon over placebo were observed among patients within the upper and lower deciles over 2 years. eGFR showed a pronounced on-treatment benefit and a delay in decline during the observation period. IN PRACTICE: 'This NefIgArd subanalysis demonstrated that the efficacy of a 9-month Nefecon treatment course in reduction of proteinuria and preservation of kidney function was independent of baseline eGFR,' said first author Jonathan Barratt, MD, of the College of Life Sciences, University of Leicester, UK. 'So, we should be confident about treating people with Nefecon across the full range of eGFR in terms of the eGFR saving we're going to see, but also the proteinuria reduction,' he added. SOURCE: The findings were reported this week at the 62nd European Renal Association (ERA) Congress 2025. DISCLOSURES: The study was funded by Calliditas Therapeutics AB. Credit Lead image: Medscape Medscape Medical News © 2025 WebMD, LLC Cite this: Nefecon Shows IgAN Benefits Regardless of Baseline eGFR - Medscape - June 06, 2025.
